Parkinson's Disease Research
Parkinson's Disease
ResearchActive
Key Facts
About ProgenaBiome
Founded in 2017, ProgenaBiome is a private, physician-owned genetic research lab that bridges microbiome science and clinical application. Its core business involves providing microbiome testing services (the Flora Test) to physicians and patients while actively conducting research into the role of the gut microbiome in various diseases, including Parkinson's. The company's strategy centers on validating sequencing data for clinical use, developing its refloralization (FMT) protocols, and seeking collaborations with doctors, scientists, and pharmaceutical companies. It appears to be in an early-revenue stage, generating income from testing services while funding research initiatives.
View full company profileTherapeutic Areas
Other Parkinson's Disease Drugs
| Drug | Company | Phase |
|---|---|---|
| NPT200-11 | Neuropore Therapies | Phase 1 |
| NUZ-001 | Neurizon Therapeutics | Preclinical |
| VXX-301 | Vaxxinity | Preclinical |
| BAN2802 | BioArctic | Phase 1 |
| CNM-Au8 | Clene | Phase 2 |
| hpSC-Derived Neural/Dopaminergic Cells | International Stem Cell | Preclinical/Early Clinical |
| SLS-004 | Seelos Therapeutics | Preclinical |
| SLS-007 | Seelos Therapeutics | Preclinical |
| Parkinson's Disease Portfolio (Platform-derived) | WD Pharmaceutical | Not Disclosed (Likely Preclinical/Early Clinical) |
| UX-DA001 | UniXell | Phase 1 |
| A9 Dopaminergic Neuron Therapy | Trailhead Biosystems | Pre-clinical |
| golexanolone | Umecrine Cognition | Preclinical |